https://www.selleckchem.com/pr....oducts/bay-2402234.h
These results demonstrate that TET2 mutations enhance the treatment response of MDS patients to hypomethylating agents like decitabine. These results demonstrate that TET2 mutations enhance the treatment response of MDS patients to hypomethylating agents like decitabine.The authors wish to make the following correction to this paper [...].Since path planning for multi-arm manipulators is a complicated high-dimensional problem, effective and fast path generation is not easy for the arbitrarily given start and goal locations of the en
Beğen
Yorum Yap
Paylaş
